Title |
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
---|---|
Published in |
PharmacoEconomics, March 2019
|
DOI | 10.1007/s40273-019-00792-7 |
Pubmed ID | |
Authors |
Sabine E. Grimm, Debra Fayter, Bram L. T. Ramaekers, Svenja Petersohn, Rob Riemsma, Nigel Armstrong, Xavier Pouwels, Willem Witlox, Caro Noake, Gillian Worthy, Jos Kleijnen, Manuela A. Joore |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 47 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 13% |
Researcher | 6 | 13% |
Student > Doctoral Student | 5 | 11% |
Other | 4 | 9% |
Student > Ph. D. Student | 3 | 6% |
Other | 4 | 9% |
Unknown | 19 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 23% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
Biochemistry, Genetics and Molecular Biology | 2 | 4% |
Economics, Econometrics and Finance | 2 | 4% |
Business, Management and Accounting | 2 | 4% |
Other | 8 | 17% |
Unknown | 19 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 July 2020.
All research outputs
#15,566,052
of 23,136,540 outputs
Outputs from PharmacoEconomics
#1,551
of 1,868 outputs
Outputs of similar age
#220,039
of 351,663 outputs
Outputs of similar age from PharmacoEconomics
#24
of 40 outputs
Altmetric has tracked 23,136,540 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,868 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,663 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.